J.P. Morgan raises Novo Nordisk target on stronger Ozempic, Wegovy sales
J.P. Morgan raised its 2027 price target for Novo Nordisk (NVO) to 275 DKK from 250 DKK, citing stronger sales forecasts for Ozempic and Wegovy. The broker increased 2026-2030 EPS forecasts by 4-8%, expecting 1% sales growth in 2027. Ozempic's forecast was raised by 8% to 113B DKK, while Oral Wegovy's was cut by 11% to 18B DKK.
How this was made
The 30-second read
Why it matters
The upgrade could trigger buying pressure, especially in the short term, as traders adjust positions to the new target.
Market read
Analyst target raise for a major pharma player can move the stock and influence sector sentiment.
What to watch
Potential regulatory pressure on GLP‑1 drugs and generic competition could limit upside.
Background
J.P. Morgan's note follows Novo Nordisk's Q2 2026 results and reflects expectations for its GLP‑1 portfolio.
Ticker impact
J.P. Morgan raised its price target for Novo Nordisk to 275 crowns and increased its 2026 sales forecasts for Ozempic and Wegovy.
Potential short-term rally as investors price in higher target.
Target raise and higher sales forecasts are fresh, material analyst actions that can move the stock immediately.
Market effects
Positive for the diabetes/obesity drug sector as higher forecasts may lift peers.
European pharma stocks could benefit from the upbeat outlook.
Novo Nordisk is a global leader; its upgraded outlook may influence global healthcare indices.
Counterpoint
The target raise may already be priced in; risk of overvaluation remains.
Key entities
- companyNovo Nordisk
Danish pharmaceutical company specializing in diabetes and obesity treatments.
- analystJ.P. Morgan
Investment bank providing the upgraded price target and sales forecasts.
